Human parathyroid hormone 1-34 reverses bone loss in ovariectomized mice

J. M. Alexander, I. Bab, S. Fish, R. Müller, T. Uchiyama, G. Gronowicz, M. Nahounou, Q. Zhao, D. W. White, M. Chorev, D. Gazit, M. Rosenblatt

    Research output: Contribution to journalArticlepeer-review

    65 Citations (Scopus)


    The experimental work characterizing the anabolic effect of parathyroid hormone (PTH) in bone has been performed in nonmurine ovariectomized (OVX) animals, mainly rats. A major drawback of these animal models is their inaccessibility to genetic manipulations such as gene knockout and overexpression. Therefore, this study on PTH anabolic activity was carried out in OVX mice that can be manipulated genetically in future studies. Adult Swiss-Webster mice were OVX, and after the fifth postoperative week were treated intermittently with human PTH(1-34) [hPTH(1-34)] or vehicle for 4 weeks. Femoral bones were evaluated by microcomputed tomography (μCT) followed by histomorphometry. A tight correlation was observed between trabecular density (BV/TV) determinations made by both methods. The BV/TV showed >60% loss in the distal metaphysis in 5-week and 9-week post-OVX, non-PTH-treated animals. PTH induced a ∼35% recovery of this loss and a ∼40% reversal of the associated decreases in trabecular number (Tb.N) and connectivity. PTH also caused a shift from single to double calcein-labeled trabecular surfaces, a significant enhancement in the mineralizing perimeter and a respective 2- and 3-fold stimulation of the mineral appositional rate (MAR) and bone formation rate (BFR). Diaphyseal endosteal cortical MAR and thickness also were increased with a high correlation between these parameters. These data show that OVX osteoporotic mice respond to PTH by increased osteoblast activity and the consequent restoration of trabecular network. The Swiss-Webster mouse model will be useful in future studies investigating molecular mechanisms involved in the pathogenesis and treatment of osteoporosis, including the mechanisms of action of known and future bone antiresorptive and anabolic agents.

    Original languageEnglish
    Pages (from-to)1665-1673
    Number of pages9
    JournalJournal of Bone and Mineral Research
    Issue number9
    Publication statusPublished - 2001


    • Bone anabolic agents
    • Bone loss
    • Mouse
    • Osteoporosis
    • Ovariectomy
    • Parathyroid hormone

    ASJC Scopus subject areas

    • Surgery


    Dive into the research topics of 'Human parathyroid hormone 1-34 reverses bone loss in ovariectomized mice'. Together they form a unique fingerprint.

    Cite this